Home Cart Sign in  
Chemical Structure| 1403257-80-6 Chemical Structure| 1403257-80-6
Chemical Structure| 1403257-80-6

*Storage: Sealed in dry,Room Temperature.

*Shipping: Normal

5-Bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide

CAS No.: 1403257-80-6

4.5 *For Research Use Only !

Cat. No.: A773420 Purity: 98% (contains 2-3%DCM)

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
100mg łîǶÊÊ Inquiry Inquiry Login
250mg łÇÍʶÊÊ Inquiry Inquiry Login
1g ł§òî¶ÊÊ Inquiry Inquiry Login
5g łÇËîʶÊÊ Inquiry Inquiry Login

Please Login or Create an Account to: See VIP prices and availability

  • 100mg

    łîǶÊÊ

  • 250mg

    łÇÍʶÊÊ

  • 1g

    ł§òî¶ÊÊ

  • 5g

    łÇËîʶÊÊ

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Details of [ 1403257-80-6 ]

CAS No. :1403257-80-6
Formula : C23H30BrN3O3
M.W : 476.41
SMILES Code : O=C(NCC1=C(C)C=C(C)NC1=O)C2=CC(Br)=CC(N(CC)C3CCOCC3)=C2C
MDL No. :MFCD28167870
InChI Key :FADJTYGNEWCCFM-UHFFFAOYSA-N
Pubchem ID :66576790

Safety of [ 1403257-80-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Calculated chemistry of [ 1403257-80-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 30
Num. arom. heavy atoms 12
Fraction Csp3 0.48
Num. rotatable bonds 7
Num. H-bond acceptors 3.0
Num. H-bond donors 2.0
Molar Refractivity 124.36
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

74.43 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.55
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.78
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

3.85
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.93
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

5.41
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

3.9

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-5.01
Solubility 0.00467 mg/ml ; 0.00000979 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-5.04
Solubility 0.00438 mg/ml ; 0.00000919 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-7.74
Solubility 0.00000863 mg/ml ; 0.0000000181 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.52 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.4

Application In Synthesis [ 1403257-80-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1403257-80-6 ]
  • Downstream synthetic route of [ 1403257-80-6 ]

[ 1403257-80-6 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 1403257-80-6 ]
  • [ 364794-79-6 ]
  • [ 1403254-99-8 ]
YieldReaction ConditionsOperation in experiment
71% With sodium carbonate In 1,4-dioxane; water; acetonitrile at 100℃; for 4 h; Inert atmosphere Step 7:
Synthesis of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
To a stirred solution of 5-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide (14 g, 29.5 mmol) in dioxane/water mixture (70 mL/14 mL) was added 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine (13.4 g, 44.2 mmol) followed by addition of Na2CO3 (11.2 g, 106.1 mmol).
The solution was purged with argon for 15 minutes and then Pd (PPh3)4 (3.40 g, 2.94 mmol) was added and the solution was again purged with argon for a further 10 min.
The reaction mixture was heated at 100° C. for 4 h.
After completion (monitored by TLC), the reaction mixture was diluted with water and extracted with 10percent MeOH/DCM.
The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.
The crude compound was purified by column chromatography (100-200 mesh silica gel) eluting with methanol: DCM to the title compound as a solid (12 g, 71percent).
Analytical Data: LCMS: 573.35 (M+1)+; HPLC: 99.5percent ( 254 nm) (Rt; 3.999; Method: Column: YMC ODS-A 150 mm*4.6 mm*5μ; Mobile Phase: A; 0.05percent TFA in water/B; 0.05percent TFA in acetonitrile; Inj. Vol: 10 μL, Col. Temp.: 30° C.; Flow rate: 1.4 mL/min.;
Gradient: 5percent B to 95percent B in 8 min, Hold for 1.5 min, 9.51-12 min 5percent B); 1H NMR (DMSO-d6, 400 MHz) δ 11.46 (s, 1H), 8.19 (t, 1H), 7.57 (d, 2H, J=7.2 Hz), 7.36-7.39 (m, 3H), 7.21 (s, 1H), 5.85 (s, 1H), 4.28 (d, 2H, J=2.8 Hz), 3.82 (d, 2H, J=9.6 Hz), 3.57 (bs, 4H), 3.48 (s, 2H), 3.24 (t, 2H, J=10.8 Hz), 3.07-3.09 (m, 2H), 3.01 (m, 1H), 2.36 (m, 4H), 2.24 (s, 3H), 2.20 (s, 3H), 2.10 (s, 3H), 1.64-1.67 (m, 2H), 1.51-1.53 (m, 2H), 0.83 (t, 3H, J=6.4 Hz).
71%
Stage #1: With sodium carbonate In 1,4-dioxane; water for 0.25 h; Inert atmosphere
Stage #2: With tetrakis(triphenylphosphine) palladium(0) In 1,4-dioxane at 100℃; for 4.2 h; Inert atmosphere
[0336] Step 7: Synthesis of N-((4, 6-dimethyl-2-oxo-l, 2-dihydropyridin-3-yl) methyl)-5- (ethyl (tetrahydro-2H-pyran-4-yl) amino)-4-methyl-4'-(morpholinomethyl)-[l, l'-biphenyl]-3- carboxamide [0337] To a stirred solution of 5-bromo-N-((4, 6-dimethyl-2-oxo-l, 2-dihydropyridin-3-yl) methyl)-3-(ethyl (tetrahydro-2H-pyran-4-yl) amino)-2-methylbenzamide (14 g, 29.5 mmol) in dioxane/ water mixture (70 mL/14 mL) was added 4-(4-(4, 4, 5, 5-tetramethyl-l, 3, 2- dioxaborolan-2-yl) benzyl) morpholine (13.4 g, 44.2 mmol) followed by addition of Na2C03 (11.2 g, 106.1 mmol). The solution was purged with argon for 15 minutes and then Pd (PPh )4 (3.40 g, 2.94 mmol) was added and the solution was again purged with argon for a further 10 min. The reaction mixture was heated at 100°C for 4 h. After completion (monitored by TLC), the reaction mixture was diluted with water and extracted with 10percent MeOH/DCM. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The crude compound was purified by column chromatography (100- 200 mesh silica gel) eluting with methanol: DCM to the title compound as a solid (12 g, 71 percent). Analytical Data: LCMS: 573.35 (M + 1)+; HPLC: 99.5percent ( 254 nm) (R,;3.999; Method: Column: YMC ODS-A 150 mm x 4.6 mm x 5 μ; Mobile Phase: A; 0.05percent TFA in water/ B; 0.05percent TFA in acetonitrile; Inj. Vol: 10 μ, Col. Temp.: 30 °C; Flow rate: 1.4 mL/min.; Gradient: 5percent B to 95percent B in 8 min, Hold for 1.5 min, 9.51-12 min 5percent B); 1H NMR (DMSO-J6, 400 MHz) δ 11.46 (s, 1H), 8.19 (t, 1H), 7.57 (d, 2H, J=7.2 Hz), 7.36-7.39 (m, 3H), 7.21 (s, 1H), 5.85 (s, 1H), 4.28 (d, 2H, J=2.8 Hz), 3.82 (d, 2H, J=9.6 Hz), 3.57 (bs, 4H), 3.48 (s, 2H), 3.24 (t, 2H, J=10.8Hz), 3.07-3.09 (m, 2H), 3.01 (m, 1H), 2.36 (m, 4H), 2.24 (s, 3H), 2.20 (s, 3H), 2.10 (s, 3H), 1.64-1.67 (m, 2H), 1.51-1.53 (m, 2H), 0.83 (t, 3H, J=6.4 Hz).
71% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In 1,4-dioxane; water at 100℃; for 4 h; Inert atmosphere N - [(4,6- dimethyl-2-carboxy-1,2-dihydro-3-pyridyl) methyl] -2-methyl-3- [ethyl (tetrahydro -2H- 4- pyran-yl) amino] -5-carboxamide bromobenzene (14g, 29.5mmol) was dissolved in dioxane / water mixture (70mL /14mL), added with stirring 4- (4-morpholino-methyl) phenylboronic acid pinacol ester (13.4g, 44.2mmol), followed by the addition of sodium carbonate (11.2g, 105.7mmol). Solution was purged with argon for 15min, then add tetrakis (triphenylphosphine) palladium (3.40g, 2.94mmol), a solution of purified argon and then 10min. The reaction mixture was heated to 100 reaction 4h. Tracking progress of the reaction TLC, eluent: methanol / dichloromethane (1:10), add water, 50mL, methanol / dichloromethane: extraction (19). The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was chromatographed on silica gel column, eluent: methanol / dichloromethane (1:10) to give a solid product 12g, Yield 71percent
References: [1] Patent: US2012/264734, 2012, A1, . Location in patent: Page/Page column 128.
[2] Patent: WO2013/155464, 2013, A1, . Location in patent: Paragraph 0336; 0337.
[3] Journal of Medicinal Chemistry, 2016, vol. 59, # 4, p. 1556 - 1564.
[4] Patent: CN105440023, 2016, A, . Location in patent: Paragraph 0090; 0091; 0092.
 

Related Products

Historical Records

Technical Information

Categories